Get the Stockscreener App
22.29
0.45%
0.10
Tango Therapeutics Inc stock is traded at $22.29, with a volume of 1.50M.
It is up +0.45% in the last 24 hours and down -6.70% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$22.19
Open:
$22.265
24h Volume:
1.50M
Relative Volume:
0.36
Market Cap:
$3.76B
Revenue:
$56.99M
Net Income/Loss:
$-107.23M
P/E Ratio:
-27.19
EPS:
-0.8199
Net Cash Flow:
$-142.55M
1W Performance:
-1.24%
1M Performance:
-6.70%
6M Performance:
-12.00%
1Y Performance:
+134.14%
1-Day Range:
$21.79
$22.96
1-Week Range:
$21.52
$24.47
52-Week Range:
$6.69
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
22.29 | 3.76B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-26 | Initiated | JP Morgan | Overweight |
| Jun-26-26 | Upgrade | Jefferies | Hold → Buy |
| Jun-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-26 | Downgrade | Jefferies | Buy → Hold |
| Apr-02-26 | Initiated | Canaccord Genuity | Buy |
| Feb-23-26 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Why Tango Therapeutics Shares Are Falling Today - Quiver Quantitative
JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data - Investing.com
Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com South Africa
Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com Australia
Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com UK
Form 4 Tango Therapeutics Inc For: 5 October By Investing.com - Investing.com Canada
Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com
Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com Canada
Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares - Stock Titan
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com South Africa
Tango Therapeutics principal accounting officer sells $198k in stock - Investing.com
Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. - Stock Titan
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Eastern Progress
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com India
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com Canada
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance
Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
Tango Therapeutics appoints Robert Azelby to Board of Directors - scanx.trade
HC Wainwright Issues Pessimistic Outlook for TNGX Earnings - MarketBeat
Research Analysts Issue Forecasts for TNGX Q2 Earnings - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada
H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com
H.C. Wainwright raises Tango Therapeutics price target to $68 - investing.com
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com
Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada
Early trial shows strong pancreatic cancer resp... - Pluang
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tango Therapeutics Inc Stock (TNGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Oct 01 '26 |
Sale |
24.47 |
27,000 |
660,796 |
115,743 |
| Jessica Newcomb | Officer |
Sep 22 '26 |
Proposed Sale |
22.33 |
15,231 |
340,108 |
0 |
| Newcomb Jessica | Principal Accounting Officer |
Sep 22 '26 |
Sale |
24.22 |
8,200 |
198,613 |
59,121 |
| Crystal Adam | President, R&D |
Sep 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
| Crystal Adam | President, R&D |
Sep 01 '26 |
Sale |
22.37 |
27,000 |
603,909 |
115,743 |
| Crystal Adam | President, R&D |
Aug 03 '26 |
Sale |
27.24 |
27,000 |
735,517 |
115,743 |
| ADAM CRYSTAL | Officer |
Aug 03 '26 |
Proposed Sale |
27.18 |
81,000 |
2,201,580 |
0 |
| Crystal Adam | President, R&D |
Aug 03 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
| Crystal Adam | President, R&D |
Jul 01 '26 |
Sale |
29.59 |
27,000 |
798,908 |
115,743 |
| Crystal Adam | President, R&D |
Jul 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
2.23%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):